Contact
searchSearch
HMP Global

Peripheral Arterial Disease Presentations

Mike Watts, MD, FSIR
AMP 2026
When Economics Meets Innovation: Matching Deep Venous Arterialization to the Right Site of Service
08/07/2026
Mike Watts, MD, FSIR
08/07/2026
Vascular Disease Management
Dr Yana Etkin
AMP 2026
Early Detection and Timely Reintervention Drive Success After Deep Venous Arterialization
08/07/2026
Yana Etkin, MD, FSVS, FACS
Yana Etkin, MD,  presented an in-depth review of strategies for identifying and managing failing DVA, emphasizing that long-term success depends not only on creating the DVA circuit but also on maintaining its patency through vigilant...
Yana Etkin, MD,  presented an in-depth review of strategies for identifying and managing failing DVA, emphasizing that long-term success depends not only on creating the DVA circuit but also on maintaining its patency through vigilant...
Yana Etkin, MD,  presented an...
08/07/2026
Vascular Disease Management
Alik Farber, MD
AMP 2026
Four-Year BEST-CLI Data Reinforce a Team-Based Future for Limb Salvage
08/07/2026
Alik Farber, MD
Alik Farber, MD, MBA, presented the latest 4-year findings from the landmark BEST-CLI trial. He challenged attendees to move beyond the long-standing debate of surgery vs endovascular intervention and instead embrace an evidence-based,...
Alik Farber, MD, MBA, presented the latest 4-year findings from the landmark BEST-CLI trial. He challenged attendees to move beyond the long-standing debate of surgery vs endovascular intervention and instead embrace an evidence-based,...
Alik Farber, MD, MBA, presented...
08/07/2026
Vascular Disease Management
Dr Eric Secemsky
AMP 2026
Defining Optimal Medical Therapy for CLTI in 2026
08/07/2026
Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI
Dr Eric Secemsky presented a review of the evidence supporting contemporary medical management for patients with PAD and CLTI, emphasizing that pharmacologic therapy remains an essential pillar of reducing cardiovascular events.
Dr Eric Secemsky presented a review of the evidence supporting contemporary medical management for patients with PAD and CLTI, emphasizing that pharmacologic therapy remains an essential pillar of reducing cardiovascular events.
Dr Eric Secemsky presented a...
08/07/2026
Vascular Disease Management
Dr Ralf Langhoff
AMP 2026
Retrograde Access Moves to the Forefront: Rethinking CTO Crossing Strategies
08/06/2026
Ralf Langhoff, MD
During a Thursday afternoon session at the Amputation Prevention Symposium 2026, Ralf Langhoff, MD, asked attendees to reconsider when retrograde access should be used for chronic total occlusion (CTO) interventions.
During a Thursday afternoon session at the Amputation Prevention Symposium 2026, Ralf Langhoff, MD, asked attendees to reconsider when retrograde access should be used for chronic total occlusion (CTO) interventions.
During a Thursday afternoon...
08/06/2026
Vascular Disease Management
Dr Ramon Varcoe
AMP 2026
Bioresorbable Below-the-Knee Technology Shows Durable Promise for CLTI
08/06/2026
Ramon L. Varcoe, MBBS, MS, PhD
Dr Ramon L. Varcoe presented an update on bioresorbable BTK technology, highlighting the growing body of evidence supporting the Esprit™ BTK drug-eluting resorbable scaffold (Abbott Cardiovascular) for the treatment of CLTI.
Dr Ramon L. Varcoe presented an update on bioresorbable BTK technology, highlighting the growing body of evidence supporting the Esprit™ BTK drug-eluting resorbable scaffold (Abbott Cardiovascular) for the treatment of CLTI.
Dr Ramon L. Varcoe presented an...
08/06/2026
Vascular Disease Management
Dr Pradeep Nair
AMP 2026
A New Approach to Crossing and Preparing Complex Peripheral Chronic Total Occlusions
08/06/2026
Pradeep K. Nair, MD, FACC, FSCAI
Dr Pradeep K. Nair presented the clinical rationale, engineering design, pivotal clinical data, and early real-world experience with the Santreva-ATK Endovascular Revascularization Catheter (AngioSafe).
Dr Pradeep K. Nair presented the clinical rationale, engineering design, pivotal clinical data, and early real-world experience with the Santreva-ATK Endovascular Revascularization Catheter (AngioSafe).
Dr Pradeep K. Nair presented the...
08/06/2026
Vascular Disease Management
S Jay Mathews, MD
AMP 2026
SELUTION SLR Highlights the Growing Role of Sirolimus Drug-Eluting Balloons in CLTI
08/06/2026
S. Jay Mathews, MD, MS, FACC, FSCAI
This presentation examined the evolving evidence supporting the SELUTION SLR sirolimus drug-eluting balloon (Cordis) as a treatment strategy for femoropopliteal and BTK PAD, with particular emphasis on complex CLTI.
This presentation examined the evolving evidence supporting the SELUTION SLR sirolimus drug-eluting balloon (Cordis) as a treatment strategy for femoropopliteal and BTK PAD, with particular emphasis on complex CLTI.
This presentation examined the...
08/06/2026
Vascular Disease Management
Tim Wittig, MD
AMP 2026
MOTIV BTK Trial Demonstrates Promising Early Outcomes for Sirolimus-Eluting Bioresorbable Scaffold in CLTI
08/05/2026
Tim Wittig, MD
Tim Wittig, MD, presents the primary outcomes from the MOTIV BTK Trial, which evaluated the safety and efficacy of the sirolimus-eluting bioresorbable scaffold MOTIV BTK.
Tim Wittig, MD, presents the primary outcomes from the MOTIV BTK Trial, which evaluated the safety and efficacy of the sirolimus-eluting bioresorbable scaffold MOTIV BTK.
Tim Wittig, MD, presents the...
08/05/2026
Vascular Disease Management
Dr Eric Scott
AMP 2026
Using Imaging to Choose Between Endovascular Therapy and Surgical Bypass
08/05/2026
Eric C. Scott, MD
Dr Eric Scott presents presents a case-based discussion on how advanced vascular imaging should guide the decision between an endovascular-first or surgical bypass-first approach for patients with PAD and CLTI.
Dr Eric Scott presents presents a case-based discussion on how advanced vascular imaging should guide the decision between an endovascular-first or surgical bypass-first approach for patients with PAD and CLTI.
Dr Eric Scott presents presents...
08/05/2026
Vascular Disease Management

Stay in the Know

Vascular Disease Management Newsletter

News

Press Release
Fluidx Completes Submission of Premarket Approval Application for the GPX® Embolic Device
07/24/2026
Salt Lake City (UT) – 07/24/2026 Fluidx Medical Technology, Inc., a clinical stage medical device company advancing its portfolio of embolic technologies, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the...
Salt Lake City (UT) – 07/24/2026 Fluidx Medical Technology, Inc., a clinical stage medical device company advancing its portfolio of embolic technologies, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the...
Salt Lake City (UT) – 07/24/2026...
07/24/2026
Vascular Disease Management
Thrombectomy
THUNDER Study Demonstrates Penumbra’s THUNDERBOLT is Safe and Effective for Stroke Care
07/22/2026
ALAMEDA, Calif. – Penumbra, Inc. announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company’s novel...
ALAMEDA, Calif. – Penumbra, Inc. announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company’s novel...
ALAMEDA, Calif....
07/22/2026
Cath Lab Digest
Stroke Interventions
Imperative Care Launches Ikon 24 Pro Guidewire, Enhancing the Zoom Stroke System to Support More Efficient Stroke Procedures
07/17/2026
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
CAMPBELL, Calif., July 16, 2026...
07/17/2026
Vascular Disease Management
Liver Tumor Ablation
First Meta-analysis Supports Histotripsy for Liver Tumor Ablation
07/14/2026
Laura Simson, MA
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high...
07/14/2026
Vascular Disease Management
Radiation Safety
Landmark Multi-Society Consensus Signals New Era in Occupational Radiation Safety; Rampart Positioned to Accelerate Adoption of Lead-Free Enhanced Radiation Protection
07/14/2026
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
BIRMINGHAM, Ala. — July 14, 2026...
07/14/2026
Vascular Disease Management
GPX Embolic Device
GPX® Embolic Device Meets Primary Endpoints in an Investigational Device Exemption (IDE) Pivotal Trial
07/14/2026
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx...
07/14/2026
Vascular Disease Management
Transarterial Chemoembolization
STRIDE-Based Regimens Plus TACE Improve Outcomes vs TACE Alone in Embolization-Eligible Hepatocellular Carcinoma
07/13/2026
Stephanie Holland
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3...
07/13/2026
Vascular Disease Management
Peripheral Intervention
3-Year DETOUR2 Results Demonstrate Sustained Symptom Relief and Limb Preservation in Complex SFA Disease
07/09/2026
Data from one of the first studies in long-segment (>30 cm) FP disease show durable patency, low reintervention rate, and high limb salvage through 36 months.
Data from one of the first studies in long-segment (>30 cm) FP disease show durable patency, low reintervention rate, and high limb salvage through 36 months.
Data from one of the first...
07/09/2026
Cath Lab Digest
Thrombectomy for Stroke
First Patient Enrolled in Penumbra’s FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
07/07/2026
ALAMEDA, Calif. - Penumbra, Inc. announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical thrombectomy, including computer...
ALAMEDA, Calif. - Penumbra, Inc. announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical thrombectomy, including computer...
ALAMEDA, Calif. - Penumbra, Inc....
07/07/2026
Cath Lab Digest
Embolization
Fluidx Announces Continued Clinical Success with ULTRA Embolic Gel
07/02/2026
SALT LAKE CITY, UT — July 02, 2026 — Fluidx Medical Technology, Inc. today announced that its ULTRA Embolic Device continues to see clinical success and was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumor at...
SALT LAKE CITY, UT — July 02, 2026 — Fluidx Medical Technology, Inc. today announced that its ULTRA Embolic Device continues to see clinical success and was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumor at...
SALT LAKE CITY, UT — July 02,...
07/02/2026
Vascular Disease Management

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use